PCN103 The Adjuvant Treatment of Stage 3 Colon Cancer (aCC): An Indirect Cost-Minimisation and Population Net Health Benefit Analysis of Capecitabine + Oxaliplatin (XELOX) vs. iv 5-FU + FA + Oxaliplatin (FOLFOX)

✍ Scribed by Garside, J.; McNamara, S.; Millar, D.

• Book ID: 122012308
• Publisher: John Wiley and Sons
• Year: 2011
• Tongue: English
• Weight: 61 KB
• Volume: 14
• Category: Article
• ISSN: 1098-3015
• DOI: 10.1016/j.jval.2011.08.1204